Seagen And Astellas Pharma Announced PADCEV And KEYTRUDA Significantly Improve Overall Survival And Progression-Free Survival In Patients With Previously Untreated Advanced Bladder Cancer In Pivotal Phase 3 EV-302 Trial
Portfolio Pulse from Charles Gross
Astellas Pharma and Seagen announced positive results from the Phase 3 EV-302 clinical trial for PADCEV in combination with KEYTRUDA versus chemotherapy in patients with previously untreated advanced bladder cancer. The trial enrolled patients who were eligible for cisplatin- or carboplatin-containing chemotherapy regardless of PD-L1 status.
September 22, 2023 | 9:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seagen's stock may see a positive impact due to the successful results of the Phase 3 EV-302 clinical trial for PADCEV in combination with KEYTRUDA.
Positive clinical trial results often lead to increased investor confidence and potential stock price increase. The successful results of the Phase 3 EV-302 trial for PADCEV in combination with KEYTRUDA could lead to increased sales and revenue for Seagen.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100